Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by malibukion Sep 18, 2017 12:00pm
147 Views
Post# 26709162

RE:RE:RE:RE:Deal before end of year?

RE:RE:RE:RE:Deal before end of year?

Dimension (DMTX) was also in my watch list (pity that I missed that one too while I am here) but I would say it is an exception as it is a gene theraphy company and there is a competing bid going on (previous offer from Regenxbio was 3.41 pps and today they announced 5.50 pps offer from Ultragenyx). Actually this in theory should also happen for Sirona if there are really more than one parties interested but unfortunately we do not know what is going on. Imagine the market reaction of a news release stating "Sirona received two respective terms sheets and currently in the final phase of discussions with potential partners." Such statement would not harm any negotiation I guess. Each partner probably knows what is the offer of the other side.

BTW Sirona already shared poster on Keloid previously and I also agree that it is promising. I commented in detail on it previously.
https://pbs.twimg.com/media/C-w0rShXYAEyjSd.jpg:large

I would be surprised if they did additional work on keloid. Probably they will say that there is a significant interest from big companies and they are evaluating the potential of the asset etc which is something very familiar.

If they do not share any solid progress on the update I do not think it will push the share price higher. We need to see some results rather than expect, hope, anticipate type of comments. They did not show to us and if they have had it would be a less stressfull wait for everybody. They would have less pressure from investor side and we would have felt more confident.

Let's see what the following days will bring.

GL

Bullboard Posts